KALAMAZOO, Mich., March 7, 2011 /PRNewswire/ -- Metabolic Solutions Development Company (MSDC) President and Co-Founder Jerry Colca, Ph.D. will speak on "PPAR-sparing insulin sensitizers: A new hope for the treatment of type 2 diabetes" as part of a panel discussion entitled "Diabetes and the Metabolic Syndrome Drug Development" on Tuesday, March 8 at 8 a.m. at the Diabetes Summit in Philadelphia.
Joining Colca on the panel is William Washburn of Bristol-Myers Squibb; Paul Burton of Johnson & Johnson; Jeffrey Pfefferkorn of Pfizer; and Jerome J. Schentag of the University at Buffalo. The fourth annual Diabetes Summit is hosted by the GTCbio, a division of the Global Technology Community.
MSDC is a clinical-stage company developing innovative therapeutics to treat diabetes. The company's lead candidate, MSDC-0160, is currently in a 90-day, multinational Phase 2b study involving more than 420 patients throughout the United States and India. A Phase 2a trial of MSDC-0160 demonstrated that it can improve insulin sensitivity and lower blood glucose levels in humans without the side effects of the current market-leading diabetes medicines.
About Metabolic Solutions Development Company (MSDC)
Metabolic Solutions Development Company (www.msdrx.com) is a drug discovery and development company exploiting novel molecular targets to develop new therapies for metabolic diseases associated with altered mitochondrial function, especially insulin resistance and type 2 diabetes. The company has raised nearly $50 million in support of the development of its pioneer and lead products, MSDC-0160 and MSDC-0602, which are new insulin sensitizers that work through a novel mitochondrial molecular mechanism of action and which have been shown to be effective in reducing fasting plasma glucose without the unwanted side effects associated with PPARy activation. Founded in 2006 by former Pfizer researchers Jerry Colca, Ph.D. and Rolf Kletzien, Ph.D., MSDC is headquartered in Kalamazoo, Mich.
SOURCE Metabolic Solutions Development Company